Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
Joseph Mikhael, MD, MEd, FRCPC, FACP
Conference Coverage
Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?
04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates &...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, MEd, FRCPC, FACP
Conference Coverage
Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?
04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates &...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment
04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates &...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment
04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates &...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
Jessica Altman, MD
Conference Coverage
Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
04/09/2024

Featuring Jessica Altman, MD

Featuring Jessica Altman, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates &...
04/09/2024
Oncology
Jessica Altman, MD
Conference Coverage
Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
04/09/2024

Featuring Jessica Altman, MD

Featuring Jessica Altman, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates &...
04/09/2024
Oncology

Advertisement

About

At Great Debates and Updates in Hematologic Malignancies, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of hematology and oncology.

Through comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Platinum Sponsors

johnson & johnson

 

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use